Turalio

Active Ingredient(s): Pexidartinib Hydrochloride
FDA Approved: * August 2, 2019
Pharm Company: * DAIICHI SANKYO INC

Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R). [1][2][3][4] Common side effects are increased lactate dehydrogenase (proteins tha... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Turalio 200 mg Oral Capsule

NDC: 65597-402

Labeler:

Daiichi Sankyo Inc.

Turalio 125 mg Oral Capsule

NDC: 65597-407

Labeler:

Daiichi Sankyo, Inc.